SEC Form 4 · accession 0000899243-17-005227
NovoCure Ltd · NVCR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Eilon D. Kirson
Officer — Chief Scientific Officer
Period of report
Feb 22, 2017
Accepted (ET)
Feb 24, 2017 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645113
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Buy Ordinary SharesF1 | $7.15 | Feb 22, 2017 | A | 273,000 | A | — | Feb 22, 2027 | Ordinary Shares | 273,000 | 273,000 | D |
| Restricted Stock UnitF2,F3 | — | Feb 22, 2017 | A | 109,200 | A | — | — | Ordinary Shares | 109,200 | 109,200 | D |
Explanation of responses
- F1Options to buy 273,000 ordinary shares will vest and become exercisable in equal installments on each of February 22, 2018, 2019, 2020 and 2021, subject to Mr. Kirson's continued employment through such dates.
- F2Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.
- F3One-third of these restricted stock units are scheduled to vest on each of February 22, 2018, February 22, 2019, and February 22, 2020, subject to Mr. Kirson's continued employment through such dates.